|
|
Vaccine Detail
|
mRNA-1273.214 |
| Vaccine Information |
- Vaccine Name: mRNA-1273.214
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Moderna
- Vaccine Ontology ID: VO_0005415
- Type: mRNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccination Protocol: In this ongoing, phase 2-3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster (Chalkias et al., 2022)
- Efficacy: Vaccine effectiveness was not assessed in this study; in an exploratory analysis, SARS-CoV-2 infection occurred in 11 participants after the mRNA-1273.214 booster and in 9 participants after the mRNA-1273 booster. The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Chalkias et al., 2022)
|
| References |
Chalkias et al., 2022: Spyros Chalkias 1, Charles Harper 1, Keith Vrbicky 1, Stephen R Walsh 1, Brandon Essink 1, Adam Brosz 1, Nichole McGhee 1, Joanne E Tomassini 1, Xing Chen 1, Ying Chang 1, Andrea Sutherland 1, David C Montefiori 1, Bethany Girard 1, Darin K Edwards 1, Jing Feng 1, Honghong Zhou 1, Lindsey R Baden 1, Jacqueline M Miller 1, Rituparna Das 1. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. . 2022; ; . [PubMed: 36112399].
|
|
